- Correction
- Open access
- Published:
Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation
Cancer Imaging volume 24, Article number: 82 (2024)
The Original Article was published on 07 June 2024
Correction: Mansour Cancer Imaging
Following publication of the original article [1], we were notified that due to a proofing system error, the author corrections were not submitted. These included mostly typos in the text, as well as the below corrections:
-On page 3, last sentence under Definition of measurable disease, the phrase “Two exemplary cases of MD, which is representative of the overall tumor burden are shown in Fig. 1.” should read “The distribution of MD based on the underlying solid tumor entity is shown in Fig. 1.”
-The caption for Fig. 1 should read “Distribution of measurable based on the underlying tumor entity with highest rate of MD from left to right.” instead of “Distribution of measurable and non-measurable disease based on the underlying tumor entity with highest rate of MD from left to right.”
The original article has been corrected.
Reference
Mansour, et al. Cancer Imaging. 2023;23:66. https://doi.org/10.1186/s40644-024-00708-5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s40644-024-00708-5.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Mansour, N., Heinrich, K., Zhang, D. et al. Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation. Cancer Imaging 24, 82 (2024). https://doi.org/10.1186/s40644-024-00724-5
Published:
DOI: https://doi.org/10.1186/s40644-024-00724-5